Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.17%
0%
-5.17%
6 Months
5.62%
0%
5.62%
1 Year
0%
0%
0.0%
2 Years
-14.54%
0%
-14.54%
3 Years
-8.98%
0%
-8.98%
4 Years
-41.58%
0%
-41.58%
5 Years
-7.0%
0%
-7.0%
Vétoquinol SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.45%
EBIT Growth (5y)
9.60%
EBIT to Interest (avg)
52.59
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
1.02
Tax Ratio
25.25%
Dividend Payout Ratio
17.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.10%
ROE (avg)
10.04%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.65
EV to EBIT
10.46
EV to EBITDA
7.24
EV to Capital Employed
1.94
EV to Sales
1.44
PEG Ratio
0.54
Dividend Yield
1.13%
ROCE (Latest)
18.56%
ROE (Latest)
10.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
539.20
529.30
1.87%
Operating Profit (PBDIT) excl Other Income
102.30
97.30
5.14%
Interest
1.20
1.10
9.09%
Exceptional Items
-0.80
-3.60
77.78%
Consolidate Net Profit
58.70
55.60
5.58%
Operating Profit Margin (Excl OI)
130.50%
124.20%
0.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.87% vs -1.95% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.58% vs 15.83% in Dec 2023
About Vétoquinol SA 
Vétoquinol SA
Pharmaceuticals & Biotechnology
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
Company Coordinates 
Company Details
Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex LURE None : 70204
Registrar Details






